GC Cell Signs CDMO Agreement with Dussel for Artificial Platelets

Utilizing a Stem Cell-Based Artificial Platelet Production Platform

GC Cell announced on the 10th that it has signed a contract development and manufacturing organization (CDMO) agreement with Dussel, a company specializing in artificial platelet research and development, for the stem cell-derived artificial platelet "DCB-101."

Minwoo Lee, CEO of Dussel (left), and Seongyong Won, CEO of GC Cell, are taking a commemorative photo after signing a contract for contract development and manufacturing organization (CDMO) at GC Cell's cell center located in Yongin, Gyeonggi Province on the 9th.

This agreement is a strategic collaboration aimed at accelerating the market entry of the product by utilizing Dussel's independently developed stem cell-based artificial platelet production platform to manufacture and conduct quality testing of pharmaceuticals that comply with clinical regulatory standards. The signing ceremony was held on the 9th at GC Cell's cell center in Yongin, Gyeonggi Province, with Minwoo Lee, CEO of Dussel, Seongyong Won, CEO of GC Cell, and officials from both companies in attendance.

Dussel is the first company in Korea to successfully develop an independent stem cell-based artificial platelet manufacturing platform and has been dedicated to developing innovative therapies to help address the chronic shortage of blood.

Under this agreement, GC Cell will support the advancement of Dussel's artificial platelet production process to meet Good Manufacturing Practice (GMP) standards. The company also plans to provide a "one-stop CDMO total solution," including clinical product manufacturing, characterization analysis, and quality testing. Drawing on its accumulated CDMO experience in the field of cell therapy, GC Cell will help ensure that Dussel's core pipeline can enter clinical trials reliably.

Specifically, the collaboration will support the entire process from the early stages of artificial platelet development to market launch and stable supply, including: ▲ development of cell and gene therapy processes and analytical methods; ▲ manufacturing of specialized media and raw materials for advanced biopharmaceuticals; ▲ quality analysis services in accordance with GMP standards; ▲ production for clinical trials and commercialization; and ▲ long-term storage and logistics services for advanced biopharmaceuticals.

Minwoo Lee, CEO of Dussel, stated, "We are very pleased to collaborate with GC Cell, which has GMP infrastructure and production capabilities, to successfully advance our innovative artificial platelet technology into the clinical stage." He added, "Through this partnership, Dussel's technology base and long-term production strategy will be further strengthened, and it will serve as an opportunity to secure practical execution capabilities in both clinical and commercialization stages."

Seongyong Won, CEO of GC Cell, said, "Based on GC Cell’s GMP production and quality management capabilities, we will actively support Dussel’s artificial platelet development so that it can achieve meaningful results in the market." He continued, "We will continue to seek various opportunities to establish ourselves as a leading company in the cell and gene therapy CDMO sector."